Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What Happened With McKesson Corporation (MCK)?

McKesson Corporation (NYSE:MCK) announced its results for the most recent quarter on Thursday. After beating analyst estimates for several consecutive quarters, the health care services giant announced earnings that fell far short of expectations. Shares were down 2% in after-hours trading after first dropping nearly 9%.

What happened?
McKesson reported quarterly revenue of $31.2 billion, up around 1% year-over-year. GAAP earnings came in at $1.24 per share, an increase of 3% over the same quarter in 2011. Excluding special items, earnings were $1.41 per share. The average analyst estimate was $1.63 per share.

McKesson Corporation (NYSE:MCK)How did McKesson miss so badly? It wasn’t because of revenue woes. The company did report only flat revenue for its Technology Solutions business due partially to “revenue deferral for [its] international business.” However, the segment only accounts for 3% of total revenue. Regardless, analysts were only expecting revenue of $30.8 billion for the quarter. McKesson easily beat that target.

A look at expenses, including cost of sales, tells the tale of the McKesson miss. If a company’s revenue goes up by 1% but its expenses go up by 13%, earnings are headed down. That’s what happened with McKesson. So where did all of that extra spending go?

McKesson attributed the increase in expenses in large part to a $40 million charge related to potential legal claims in Canada, which accounted for 4% of the 13% expense increase. Acquisition costs made up another 3%. Higher corporate expenses were also up $27 million, adding another 3% to operating expenses. The company noted that it tends to see considerable variability in corporate expenses from quarter to quarter.

On a positive note
Beating revenue estimates for the most recent quarter could bode well for next quarter, especially considering that some of the revenue anticipated for the quarter should actually be received in the current quarter. The company also has some major trends going in its favor, particularly with increased generic utilization.

McKesson tightened its full-year adjusted earnings guidance for fiscal year 2013 from $7.05 to $7.35 per share to $7.10 to $7.30 per share. That’s in line with analyst expectations of $7.30 per share.

The company also announced the approval of another $500 million share buyback. That comes on top of $360 million worth of shares bought back in the last quarter.

With a forward price-to-earnings ratio less than 13, McKesson still looks to be a decent buy at current prices. My hunch is that the current setback will only be a temporary one. Controlling costs more effectively is a much easier proposition than addressing sales shortfalls. McKesson’s problems should be quite solvable.

The article What Happened With McKesson? originally appeared on and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends McKesson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.